JCAR 017

Drug Profile

JCAR 017

Alternative Names: 4-1BB-modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19-EGFRt-4-1BB-zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/EGFRt/4-1BB/zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; JCAR017

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Juno Therapeutics
  • Developer Juno Therapeutics; Seattle Children's Hospital
  • Class Cancer vaccines; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Leukaemia
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 20 Dec 2016 JCAR 017 receives Breakthrough Therapy status for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA
  • 20 Dec 2016 The EMA designates PRIME status to JCA R017 for the treatment of Non-Hodgkin's lymphoma (Second-line therapy) in European Union
  • 05 Dec 2016 Phase-II clinical trials in Leukaemia (In adolescents, In children, In infants, Second-line therapy or greater, In adults) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top